ESPE Abstracts

ESPE Abstracts

Published by BioScientifica
Volume 82 | ESPE2014 | Next issue

53rd Annual ESPE (ESPE 2014)

Dublin, Ireland
18 Sept 2014 - 20 Sept 2014

Card image cap
Dublin, Ireland; 18-20 September 2014. Further information

Poster Category 2

Growth Hormone (2)

Previous section
Growth Hormone (1)
Table of contents
Next section
Growth

hrp0082p2-d3-435 | Growth Hormone (2)

First-year Growth Response to GH in Relation to Final Height Outcome in Prepubertal Children with Idiopathic GH Deficiency

hrp0082p2-d3-436 | Growth Hormone (2)

Reevaluation of GH Secretion During Puberty in Children Diagnosed as GH-deficient During Childhood

hrp0082p2-d3-437 | Growth Hormone (2)

Long-Term Effects of GH Replacement Therapy on Thyroid Function in GH Deficiency Children

hrp0082p2-d3-438 | Growth Hormone (2)

Does Priming with Sex Steroids Before GH Stimulation Test Increase the Diagnosis of Normal GH Secretion in Short Children?

hrp0082p2-d3-439 | Growth Hormone (2)

GH Dosing Patterns in Short Children Born Small for Gestational Age

hrp0082p2-d3-440 | Growth Hormone (2)

Two-Year Data from a Long-Term, Phase IV Study of Omnitrope®, a Recombinant Human GH, in Short Children Born Small for Gestational Age

hrp0082p2-d3-441 | Growth Hormone (2)

Effects of Gender and Gestational Age on GH Treatment in Very Young Children Born Small for Gestational Age

hrp0082p2-d3-442 | Growth Hormone (2)

Two-Year Results from Patro Children, a Multi-Centre, Non-Interventional Study of the Long-Term Efficacy and Safety of Omnitrope® in Children Requiring GH Treatment

hrp0082p2-d3-443 | Growth Hormone (2)

The Effect of Two Different GH Dosages on Final Height and Bone Geometry

hrp0082p2-d3-444 | Growth Hormone (2)

Baseline Body Composition of Children with Short Stature Diagnosed for GH Deficiency

hrp0082p2-d3-445 | Growth Hormone (2)

GH Treatment to Final Height in Children with Idiopathic Short Stature: Evidence for an Early Therapy Initiation Effect

hrp0082p2-d3-446 | Growth Hormone (2)

Evaluation of the Safety and Usability of FlexPro® 30 mg/3 ml, for the Delivery of Norditropin® in Patients Requiring GH Therapy

hrp0082p2-d3-447 | Growth Hormone (2)

Efficacy, Adherence, and Cost Study According to Pathology and Treatment Devices in Children Treated with GHRH

Published by BioScientifica

ESPE Abstracts

© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more